financetom
Business
financetom
/
Business
/
Intel approaches TSMC for investments or partnership, WSJ reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Intel approaches TSMC for investments or partnership, WSJ reports
Sep 25, 2025 12:41 PM

Sept 25 (Reuters) - Chipmaker Intel has

approached Taiwan Semiconductor Manufacturing Company ( TSM )

about investments in manufacturing or partnerships, the Wall

Street Journal reported on Thursday, citing people familiar with

the matter.

The development follows a Bloomberg report on Wednesday that

said Intel ( INTC ) was in talks with Apple ( AAPL ) about securing an

investment in the struggling chipmaker.

Intel's ( INTC ) efforts to get outside investment began before U.S.

President Donald Trump showed an interest in the company last

month, WSJ said, but have gone into overdrive since the U.S.

took a 10% stake in it.

Intel ( INTC ) declined to comment, while TSMC did not immediately

respond to Reuters requests for comments.

Last week, Nvidia ( NVDA ) announced it would invest $5

billion in Intel ( INTC ) for a roughly 4% stake in the company.

The chipmaker also got a $2 billion capital injection from

SoftBank Group in August.

Intel ( INTC ) CEO Lip-Bu Tan has been trying to bring in partners as

part of a turnaround at the ailing chipmaker.

Once the chip industry's flag bearer that claimed to put the

"silicon" in Silicon Valley, Intel ( INTC ) has struggled to compete in

the booming AI race, falling behind peers such as Nvidia ( NVDA ) and

Advanced Micro Devices ( AMD ).

Intel ( INTC ) has invested billions of dollars in setting up a

contract manufacturing business that has struggled to compete

with TSMC and barely attracted external customers.

The two companies had discussed a preliminary agreement to

form a joint venture, with TSMC taking a 20% stake in the new

company, the Information had reported in April.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved